In Vivo Cancer to Dendritic Cell for Cancer Immunotherapy to Achieve Durable Clinical Benefit

Highlighting the development of a new in vivo immune cell engineering modality for cancer immunotherapy, delivering differentiated therapeutic potential

Designing first-in-human clinical trial strategies for this novel approach, accelerating proof-of-concept while ensuring patient safety

Outlining future pipeline ambitions and long-term goals, driving sustained innovation and clinical impact 

Speakers:

Shane Olwill

Chief Development Officer

Asgard Therapeutics